Pharmaceuticals | Consulting Agreements | Business Contracts

Amendment to Consulting Agreement, dated March 29, 2023, by and between the Company and Dr. Jonathan Javitt (Big Rock Partners Acquisition Corp., Filed With SEC on March 31, 2023)

Consulting Agreement between the Company and Andrew Jones, dated February 15, 2023 (NovaBay Pharmaceuticals, Inc., Filed With SEC on March 31, 2023)

First Amendment to Consulting Agreement with Spartan Capital Securities, LLC (Processa Pharmaceuticals, Inc., Filed With SEC on March 30, 2023)

Consulting Agreement, between the Company and Francis Plat (Milestone Pharmaceuticals Inc., Filed With SEC on March 29, 2023)

Amendment No. 1 to Consulting Services Agreement, dated as of March 23, 2023, by and between the Company and Frank Ruffo (Aclaris Therapeutics, Inc., Filed With SEC on March 27, 2023)

Consulting Agreement by and between the Registrant and Dr. Jeffrey Heier, dated as of October 17, 2022 (OCULAR THERAPEUTIX, INC, Filed With SEC on March 6, 2023)

Consulting Agreement by and between Oramed Pharmaceuticals Inc. and Shnida Ltd., entered into as of November 1, 2022, for the services of Nadav Kidron (ORAMED PHARMACEUTICALS INC., Filed With SEC on March 6, 2023)

General Consulting and Services Agreement by and between TherapeuticsMD, Inc. and MCD Consulting Management Services, LLC, dated February 21, 2023 (TherapeuticsMD, Inc., Filed With SEC on February 27, 2023)

Consulting Agreement, dated as of January 1, 2023, by and between the Registrant and Frank Ruffo (Aclaris Therapeutics, Inc., Filed With SEC on February 23, 2023)

Consulting Agreement, dated January 3 (OptiNose, Inc., Filed With SEC on January 31, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Steven Gelone (Nabriva Therapeutics plc, Filed With SEC on January 20, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Theodore Schroeder (Nabriva Therapeutics plc, Filed With SEC on January 20, 2023)

Consulting Agreement, dated as of January 6, 2023, between KemPharm, Inc. and Travis C. Mickle, Ph.D (KEMPHARM, INC, Filed With SEC on January 9, 2023)

Consulting and Scientific Advisory Board Agreement, by and between GRI Bio, Inc. and Vipin Kumar Chaturvedi, personally or through Vidur Discoveries LLC, dated as of October 31 (Vallon Pharmaceuticals, Inc., Filed With SEC on December 23, 2022)

Consulting and Clinical Advisory Board Agreement, by and between GRI Bio, Inc. and Rohit Loomba, M.D., dated as of June 3 (Vallon Pharmaceuticals, Inc., Filed With SEC on December 23, 2022)

Consulting Agreement, dated December 16, 2022, between OptiNose US, Inc. and (OptiNose, Inc., Filed With SEC on December 16, 2022)

Consulting Agreement between MJH Research, Inc. and Viridis Biotechnology, LLC dated September 14, 2022 (MJ Holdings, Inc., Filed With SEC on November 22, 2022)

Consulting Services Agreement, dated August 31, 2022, by and between the Registrant and William P. Forbes (Trevi Therapeutics, Inc., Filed With SEC on November 10, 2022)

Consulting Agreement, effective as of August 5, 2022, between Eleison Pharmaceuticals LLC and William Fricker (Eleison Pharmaceuticals Inc, Filed With SEC on September 19, 2022)

Amendment, dated September 8, 2022, to Consulting Agreement between Adial Pharmaceuticals, Inc. and Dr. Bankole A. Johnson, dated March 24, 2019, as amended on March 22, 2022 (ADIAL PHARMACEUTICALS, INC., Filed With SEC on September 13, 2022)

Consulting Agreement, effective June 17, 2022, by and between Zomedica Corp. and Dr. Stephanie Morley (Zomedica Pharmaceuticals Corp., Filed With SEC on August 15, 2022)

Consulting Agreement, dated May 25, 2022, between Iterum Therapeutics International Limited and Dr. Michael Dunne (Iterum Therapeutics plc, Filed With SEC on August 12, 2022)

Amendment No. 2 to Consulting Agreement, dated June 17, 2022, between OncoStrategy, LLC and Context Therapeutics Inc (Context Therapeutics Inc., Filed With SEC on August 11, 2022)

Consulting Agreement between PaxMedica, Inc. and Stephen D. Sheldon, dated July 16, 2022 (PaxMedica, Inc., Filed With SEC on August 8, 2022)

Consulting Agreement, dated April 12, 2022, by and between Aaron Schacht and Elanco US Inc (Elanco Animal Health Inc, Filed With SEC on August 8, 2022)

Consulting Agreement dated June 10, 2022, by and between the Company and Bruce Polsky, M.D (Atea Pharmaceuticals, Inc., Filed With SEC on August 8, 2022)

Consulting Agreement by and between the Registrant and Dr. Michael Goldstein, dated as of June 7, 2022 (OCULAR THERAPEUTIX, INC, Filed With SEC on August 8, 2022)

SECOND AMENDMENT TO CONSULTING AGREEMENT (Bakhu Holdings, Corp., Filed With SEC on July 22, 2022)

Consulting Services Agreement by and among the Company, iAnthus Capital Management, LLC and Randy Maslow dated May 6, 2022 (iANTHUS CAPITAL HOLDINGS, INC., Filed With SEC on May 12, 2022)

Consulting Agreement, dated (Tarsus Pharmaceuticals, Inc., Filed With SEC on May 11, 2022)

Consulting Agreement, effective March 1, 2022, by and between Zomedica Inc. and Johnny D. Powers (Zomedica Pharmaceuticals Corp., Filed With SEC on May 10, 2022)

Consulting Agreement with Saleem Elmasri (Bright Green Corp, Filed With SEC on May 5, 2022)

Consulting Agreement, dated as of March 9, 2022, between Danforth Advisors, LLC and the Company (EYEGATE PHARMACEUTICALS INC, Filed With SEC on April 26, 2022)

Consulting Agreement dated April 15, 2022, by and between Herring Creek Pharmaceuticals, Inc. (as affiliate of Salzman Group) and Innovation1 Biotech Inc (GridIron BioNutrients, Inc., Filed With SEC on April 21, 2022)

Consulting Agreement, dated November 30, 2021, by and between Pulmatrix, Inc. and Danforth Advisors, LLC (Pulmatrix, Inc., Filed With SEC on April 15, 2022)

Consulting Agreement between the Company and Oren Schauble, dated March 17, 2022 (Terra Tech Corp., Filed With SEC on April 15, 2022)

Consulting Agreement, dated April 1, 2022, by and between Acreage Holdings, Inc. and R4 Holdings, LLC (Acreage Holdings, Inc., Filed With SEC on April 6, 2022)

Second Amendment dated December 1, 2021 to Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan (Angion Biomedica Corp., Filed With SEC on March 30, 2022)

Third Amendment dated March 17, 2022 to Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan (Angion Biomedica Corp., Filed With SEC on March 30, 2022)

First Amendment dated September 9, 2022 to Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan (Angion Biomedica Corp., Filed With SEC on March 30, 2022)

Pharmaceuticals (170) | Consulting Agreements (170)